Imiquimod: A novel treatment for lentigo maligna

British Journal of Dermatology

Volumn 143, Issue 4, 2000, Pages 843-845

  Ahmed, I ^a   Berth Jones, J ^a  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

Imiquimod cream; Immune modulation; Lentigo maligna; Treatment

Indexed keywords

IMIQUIMOD;

AGED; AGING; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; IMMUNOMODULATION; MALE; MALIGNANT LENTIGO; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; HUMANS; HUTCHINSON'S MELANOTIC FRECKLE; INTERFERON INDUCERS; MALE; SCALP; SKIN NEOPLASMS;

EID: 0033743997     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2000.03787.x     Document Type: Article

References (18)

1. Safety and efficacy of Imiquimod 5% cream for the treatment of Bowen's disease
2. Therapeutic response of basal cell carcinoma to the immune response modifier imiqimod 5% cream
3. Cytokine induction in mice by the immunomodulator imiquimod
4. Melanotic freckle of Hutchinson
5. Lentigo maligna and lentigo maligna melanoma
6. Treatment of lentigo maligna and lentigo maligna melanoma
7. Treatment of lentigo maligna and lentigo maligna melanoma
8. Successful treatment of lentigo maligna and lentigo maligna melanoma with Mohs' micrographic surgery aided by rush permanent sections
9. Sensitivity of pigment mucosa and skin to freeze injury
10. Treatment of lentigo maligna
11. Ten years' experience of treating lentigo maligna with topical azelaic acid
12. No effect of topical tretinoin on lentigo maligna
13. Argon laser treatment of lentigo maligna
14. Treatment of lentigo maligna with carbon dioxide laser
15. Q-switched neodymium: Yttrium-aluminum-garnet laser treatment of lentigo maligna
16. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463
17. Interferon alpha 2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
18. Intralesional interferon-alpha therapy in advanced malignant melanoma